Effect of Pentoxyfilline on Endometrial Thickness and Frozen Embryo Transfer Outcomes
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: pentoxifylline 400 mg, (control).
- Who it may be relevant to
- Registry conditions: Embryo Transfer, IVF, Infertility. Basic parameters: 18 years — 43 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The aim of this work was to investigate the effect of different vasodilators as pentoxifylline in women with unexplained infertility using IVF
Detailed description
A prospective randomized clinical study was carried out on 100 women, aged \<18 to 43 years old, has good quality day five frozen embryos. The study was done after approval from the Ethical Committee Beni Suef University Hospitals, Beni Suef, Egypt. An informed written consent was obtained from the patients.
Randomization and blindness:
An online randomization program (http://www.randomizer.org ) was used to generate a random list and each patient's code was kept in an opaque sealed envelope. Patients were randomly allocated with 1:1 allocation ratio into two equal groups in a parallel manner: Group 1 (control):
received estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) whitepills starting dose is one pill T.I.D may be increased to two pills T.I.D according to endometrial5 thickness in day 9 measured by vaginal ultrasound.
Group 2: received pentoxifylline 400 mg. Once daily in form of (Trental ® Sanofi co.) daily in addition to the above treatment protocol from the first day of the cycle until the day of starting progesterone.
All patients were subjected to complete history taking, general examination, laboratory investigations \[Anti-müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E₂), prolactin (PRL) and thyroid-stimulating hormone (TSH)\] and radiological investigations \[Ultrasonography\]. The endometrial thickness was estimated by transvaginal ultrasonography.
Interventions
- Drug pentoxifylline 400 mg
Once daily in form of (Trental ® Sanofi co.) daily in addition to the above treatment protocol from the first day of the cycle until the day of starting progesterone. - Other (control)
estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) whitepills starting dose is one pill T.I.D
Primary outcome measures
- Pregnancy [Time frame: 1 month]
Eligibility criteria
Inclusion criteria
- as good quality day five frozen embryos.
Exclusion criteria
- history of endocrine diseases,
- history of any previous surgery that couldm compromise the integrity of endometrium,
- cardiovascular, renal and liver diseases,
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Beni-suef university Hospital — Banī Suwayf
Identifiers
NCT: NCT07499817 · Trental /IVF